Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial Supplement 1. Supplement 2. eFigure 1. Number of Participants with Defined Components of Exacerbation during the MINT RCP eFigure 2. Annualized Exacerbation Rate eFigure 3. Swimmer Plots of Participants with Exacerbation during the MINT RCP eTable. Time to First Exacerbation by Week 26 (Full Analysis Set: MuSK+ Subpopulation) Supplement 3. Figure 1.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Yuwei Da
The Role of Platelet-Neutrophil Interactions in Driving Autoimmune Diseases
1 Introduction The phenomenon of platelet satellites around neutrophils, characterised by the selective adhesion of platelets to the neutrophils in whole blood, has been observed for a long time but did not gain significant attention until the 1970s [1]. Currently, flow cytometry and microscopy are the most common tools to analyse platelet–neutrophil complexes (PNCs). These tools facilitate the investigation of the dynamics of PNCs location, interactions, and function within tissues [2].
Uniparental disomy: expanding the clinical and molecular phenotypes of whole chromosomes
Introduction Uniparental disomy (UPD) refers to the inheritance of two homologous chromosomes from one parent (paternal or maternal) without the contribution of identical copies from the other parent (Engel, 1980; Benn, 2021; Gonzales et al., 2022).
Frontiers | Treatment of insomnia in myasthenia gravis-A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia
Introduction Myasthenia gravis (MG) is an antibody-mediated, cellular immune-dependent, complement-involved acquired autoimmune disease. The neuromuscular junction damage results in skeletal muscle weakness (1). Many MG patients also suffer from mental health issues such as depression, anxiety, and insomnia. This could lead to exacerbation of MG or prolonged treatment.
Danon disease in patients only with cardiac symptoms
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 16 Authors Sun YQ, Lv Q, Chen D, Da Y, Zhao XY, Dong JZ Received 11 October 2022 Accepted for publication 1 August 2023 Published 17 August 2023 Volume 2023:16 Pages 767—775 DOI https://doi.org/10.2147/PGPM.S392800 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Martin H Bluth Yu-Qing Sun,1 Qiang Lv,1 Dong Chen,2 Yuwei Da,3 Xiao-Yan Zhao,4...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yuwei
Contact Yuwei, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack